Vaithianathan Soundarya, Haidar Sam H, Zhang Xinyuan, Jiang Wenlei, Avon Christopher, Dowling Thomas C, Shao Changxing, Kane Maureen, Hoag Stephen W, Flasar Mark H, Ting Tricia Y, Polli James E
Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21201.
Food and Drug Administration, Silver Spring, Maryland 20993.
J Pharm Sci. 2016 Feb;105(2):996-1005. doi: 10.1002/jps.24643. Epub 2016 Jan 12.
The objective was to assess the impact of larger than conventional amounts of 14 commonly used excipients on Biopharmaceutics Classification System (BCS) class 3 drug absorption in humans. Cimetidine and acyclovir were used as model class 3 drugs across three separate four-way crossover bioequivalence (BE) studies (n = 24 each) in healthy human volunteers, denoted as study 1A, 1B, and 2. In study 1A and 1B, three capsule formulations of each drug were manufactured, collectively involving 14 common excipients. Capsule formulations that incorporated hydroxypropyl methylcellulose (HPMC) or magnesium stearate exhibited lower absorption. The cimetidine commercial solution contained sorbitol and also resulted in lower absorption. Hence, in study 2, two capsule formulations with lower amounts of HPMC and magnesium stearate, the sorbitol-containing commercial solution, and a sorbitol-free solution were assessed for BE. Overall, 12 common excipients were found in large amounts to not impact BCS class 3 drug absorption in humans, such that these excipients need not be qualitatively the same nor quantitatively very similar to reference, but rather simply be not more than the quantities studied here. Meanwhile, for each HPMC and microcrystalline cellulose, BCS class 3 biowaivers require these two excipients to be qualitatively the same and quantitatively very similar to the reference.
目的是评估14种常用辅料超过常规用量对人体生物药剂学分类系统(BCS)3类药物吸收的影响。在健康人类志愿者中进行了三项独立的四交叉生物等效性(BE)研究(每项研究n = 24),使用西咪替丁和阿昔洛韦作为3类模型药物,分别记为研究1A、1B和2。在研究1A和1B中,制备了每种药物的三种胶囊制剂,总共涉及14种常用辅料。含有羟丙基甲基纤维素(HPMC)或硬脂酸镁的胶囊制剂吸收较低。西咪替丁商业溶液含有山梨醇,也导致吸收较低。因此,在研究2中,评估了两种含较低量HPMC和硬脂酸镁的胶囊制剂、含山梨醇的商业溶液和无山梨醇溶液的生物等效性。总体而言,发现大量的12种常用辅料不会影响人体BCS 3类药物的吸收,因此这些辅料在质量上不必与参比制剂相同,在数量上也不必非常相似,而只需不超过此处研究的用量。同时,对于每种HPMC和微晶纤维素,BCS 3类生物豁免要求这两种辅料在质量上与参比制剂相同,在数量上非常相似。